FidoCure®
Precision Medicine for Canine Cancer

• DNA sequencing diagnostic in a CLIA certified lab
• Telemedicine-enabled clinical guidance
• Facilitated access to targeted therapy, FDA approved for humans
• Administered orally at your clinic or the patient’s home
• Complies with USP 800
Case Study

Gracie: Significant Lesion Reduction

Dr. Robert Proietto, VMD, MS treated Gracie, a 6 year old American pitbull mix, who was diagnosed with soft tissue sarcoma and thoracic metastasis. After starting FidoCure® enabled targeted therapy, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.
Gracie Tumor - Before and After
Case Study

Gracie: Significant Lesion Reduction

Dr. Robert Proietto, VMD, MS treated Gracie, a 6 year old American pitbull mix, who was diagnosed with soft tissue sarcoma and thoracic metastasis. After starting FidoCure® enabled targeted therapy, there was a significant reduction in the size of the primary lesion and complete resolution of thoracic metastasis.
Gracie Tumor - Before and After

Differentiate your practice with advanced, personalized canine cancer care.

The options to treat canine cancer are often limited, while pet parents are increasingly willing to do more for their dogs. FidoCure® enables veterinarians to differentiate their practice with advanced, personalized canine cancer care, previously only available for humans.

Human Oncology

1.6M New Annual Cases

84+ Targeted Therapies in use

84 targeted therapies humans

Veterinary Oncology

6M New Annual Cases

1 Targeted Therapy

one targeted therapy canines
84 targeted therapies humans
one targeted therapy canines

FidoCure Services

DNA Sequencing & Targeted Therapy
  • DNA sequencing helps identify the cancer’s mutations to better inform the diagnosis.
  • Veterinarians receive a DNA Report and targeted therapy treatment plan.
  • FidoCure facilitates access to recommended oral targeted therapies.
  • Recommended therapies are FDA-approved and easy to administer at home.
  • Offers alternatives to more invasive treatment or a new option when traditional therapies fail.
Therapy Only Service
  • Veterinarians receive a Data-Based Report with information about the diagnosis and recommended therapies.
  • In cases such as MCT and TCC/UC that already have widely adopted therapies, veterinarians can choose to receive expedited access to therapy.
  • Because many MCTs are c-Kit driven and TCCs are BRAF+, FidoCure facilitates access to a c-Kit targeted therapy or EGFR/HER2 and/or MEK targeted therapy.
  • Oral therapies are FDA-approved, easy to administer at home and offer an alternative to more invasive treatment or a new option when traditional therapies fail.
FidoCure by Tumor Type

FidoCure® Case Breakdown
by Tumor Type

FidoCure® Case Breakdown by Tumor Type

FidoCure by Tumor Type
White Paper

FidoCure® Precision Medicine White Paper

Read an in-depth explanation of FidoCure’s approach to precision medicine, including molecular profiling, biomarkers, and targeted therapy.
White Paper

FidoCure® Precision Medicine White Paper

Read an in-depth explanation of FidoCure’s approach to precision medicine, including molecular profiling, biomarkers, and targeted therapy.

Why Offer FidoCure® to Families

Interview with Dr. Gerald Post
Almost every cancer in humans is treated with one or a number of different targeted therapies. We believe that that’s going to be the case for veterinary oncology in the near future.

— Dr. Gerald Post · DVM MEM DACVIM
Chief Veterinary Officer, One Health Company

Hundreds of dogs have benefitted from FidoCure® options, many of which had limited other options.

Dr. Aarti Sabhlok
Dr. Aarti Sabhlok

DVM, DACVIM

“It narrows it down a little bit and gives me additional options and sometimes they’re drugs I wouldn’t have thought to use for that particular patient or that particular cancer.”

Dr. Brooke Fowler
Dr. Brooke Fowler

DVM MS DACVIM

“FidoCure® is advancing the field of veterinarian oncology by providing the technology to help vet oncologists pinpoint the genetic mutation that may be causing a dog's cancer and providing treatment alternatives that use the latest advances in human oncology.”

Dr Rob Proietto
Dr. Rob Proietto

VMD, MS

“All of our cases have done tremendous so far so I am hopeful for a long quality of life ahead”